Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2010

View Archived Issues

Nonselective inhibitor pandacostat discovered by chemical phylogenetic analysis of HDACs

Enanta Pharmaceuticals describes new antiviral agents

Merck Frosst claims new prostanoid DP2 receptor antagonists

Roche discovers novel inhibitors of Mdm2/p53 interaction

AEgera Therapeutics discloses new apoptosis inducers

Jerini identifies novel bradykinin B2 receptor ligands

Novartis optimizes lysophospholipid receptor S1P1 agonists

Raloxifene decreases epistaxis in hereditary hemorrhagic telangiectasia / News in Context

Johnson & Johnson reports new HIF prolyl hydroxylase inhibitors

Gaucher's disease patients achieve key therapeutic goals with velaglucerase alfa

Vantia discloses dysmenorrhea candidate VA-111913 at ACS meeting

Ziopharm Oncology begins phase I/II indibulin trial in breast cancer

Cedars-Sinai Medical Center launches two-drug trial in brain tumors

Transdel Pharmaceuticals raises funds for Ketotransdel trial

HRA licences additional rights for Esmya to PregLem for benign gynecological disorders

Ark Therapeutics' EG-01257 reduces tumor growth in preclinical studies

FDA issues complete response letter for ChemGenex's Omapro in CML

MaxCyte and Medinet expand license agreement for cell loading technology

Pervasis begins enrollment in phase I/II trial of PVS-10200 for restenosis prevention

Javelin intends to terminate merger agreement with Myriad following offer from Hospira

New phase II CERE-110 trial in Alzheimer's disease set to begin

Horizon Therapeutics and Nitec merge to form Horizon Pharma

MediGene licenses oHSV development program to Catherex

Gilead initiates phase III clinical Quad program in HIV

Inhibitex's phase II FV-100 trial in shingles continues as planned

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...